It will then be standard practice to publish the agendas at the start of each meeting and the minutes after their adoption the following month.
The European Medicines Agency (EMA) is publishing, for the first time, the agendas of the Committee for Medicinal Products for Human Use (CHMP), the Committee for Medicinal Products for Veterinary Use (CVMP) and the Committee for Advanced Therapies (CAT). The minutes of each of these meetings held in December will be published once they have been adopted by the relevant Committee at its meeting in January. It will then be standard practice to publish the agendas at the start of each meeting and the minutes after their adoption the following month.
This follows last week’s Management Board meeting, which cleared the way for the publication of the agendas and minutes of these three remaining EMA scientific committees. It is the final step of a process launched by the Agency in July 2012 that has already been implemented for its four other scientific committees.
“Openness of our operations is one of my key objectives. As part of this, we promised in July 2012 to start publishing agendas and minutes of all seven of our scientific committees by the end of 2013, and we are now delivering on this objective. Achieving our plan for all committees, including those giving recommendations on the marketing authorisation of medicines, the CHMP and CVMP, is a major milestone in this transparency initiative,” said Guido Rasi, Executive Director of the EMA.
“We see transparency as a priority as it is the basis for public confidence and trust in the Agency and the European Union system for the evaluation of medicines,” he added.
The Agency started publishing the agendas and minutes of its scientific committee meetings with the Pediatric Committee (PDCO) and the Pharmacovigilance Risk Assessment Committee (PRAC) in July 2012, followed by the Committee for Orphan Medicinal Products (COMP) in September 2012 and the Committee on Herbal Medicinal Products (HMPC) in September 2013.
Notes
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.